Sprycel faces multi-pronged challenge as India presses for compulsory licence
This article was originally published in Scrip
Executive Summary
The patient-versus-patent debate in India is set to reach another crescendo, this time with Bristol-Myers Squibb's anticancer Sprycel (dasatinib) under the glare as a potential second candidate for a drug compulsory license (CL) in the country.